March 18th, 2021 - March 18, 2021–NxGEN Vector Solutions’ CEO, Dr. Susan Faust, is an invited guest speaker at the Vector Engineering & Delivery for Gene Therapies summit to take place on April 20, 2021. Additional information on the presentation can be found below:

Title: Hindsight is 2020: The Advancement of CpG-depleted AAV Vectors as an Industry Standard

The desirability of CpG depletion of AAV vectors for the purpose of reducing the immune response to the vector and establishing long-term transgene expression is a hot topic in the manufacturing sector and of interest to many gene therapists. Dr. Faust is a pioneer in this research and the first to CpG-deplete AAV vectors to circumvent TLR9 activation, a technology that has become an industry standard.

The audience will gain an in depth understanding of the mechanism by which immunostimulatory CpG motifs limit transgene expression (presenting data from both preclinical and clinical studies) as well as strategies for the future design of AAV vectors.

Click here to view the Final Agenda